Medical Pharmacology Chapter 27: Gastrointestinal Pharmacology Practice Questions

Crofelemer (Mytesi):
1. Chloride channel inhibitor
2. Approved for management of HIV-drug-induced diarrhea
3. Both
4. Neither
Characteristic(process) of opioid-induced severe constipation:
1. Laxatives are usually effective in the management of opioid-induced constipation.
2. Often dietary approaches by themselves are sufficient to manage opioid-induced constipation.
3. Both
4. Neither
Approach(s) to manage opioid-Induced constipation:
1. Lubiprostone administration
2. Use of morphine receptor antagonists (peripherally restricted) such as methylnaltrexone
3. Both
4. Neither
Mu type opioid receptor antagonist(s) useful in managing opioid-induced constipation.
1. Methylnaltrexone (Relistor)
2. Alvimopan (Entereg)
3. Both
4. Neither
Methylnaltrexone:
1. Crosses the blood brain barrier
2. Does not affect CNS mediated analgesia
3. Appropriate for managing opioid-induced constipation in patients receiving palliative care and who do not respond adequately to the drugs.
4. A & B
5. B & C
6. A & C
7. A, B & C
Alvimopan:
1. Reduces duration of postoperative ileus in those patients undergoing small or large bowel resections.
2. Oral administration both before and after surgery.
3. Both
4. Neither
Alvimopan: Short-term administration limited to hospitalized patients in view of the potential for cardiovascular toxicities.
1. True
2. False
Methylnaltrexone administration:
1. Following cessation of other laxatives, methylnaltrexone is administered by subcutaneous injection (adults with chronic noncancer pain)
2. Opioid withdrawal symptoms may occur if patients have a compromised blood-brain barrier.
3. Both
4. Neither
Administration of methylnaltrexone to patients who may have orhave beenn shown to have a G.I. obstruction may result in bowel perforation.
1. True
2. False

Medical Pharmacology: Gastrointestinal Pharmacology Practice Questions